Teva Pharmaceutical Industries Limited (TLV:TEVA)
Market Cap | 74.99B |
Revenue (ttm) | 56.02B |
Net Income (ttm) | -528.98M |
Shares Out | n/a |
EPS (ttm) | -0.47 |
PE Ratio | n/a |
Forward PE | 7.73 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,186,658 |
Average Volume | 1,417,796 |
Open | 6,620.00 |
Previous Close | 6,640.00 |
Day's Range | 6,575.00 - 6,644.00 |
52-Week Range | 4,865.00 - 8,431.00 |
Beta | 0.71 |
RSI | 63.49 |
Earnings Date | Nov 5, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
Teva Pharmaceutical Industries is regaining investor interest as restructuring efforts drive margin improvements. Read why TEVA stock is a Buy.
FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors
FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors
JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News
JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus
Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE: TEVA). And retail traders should know. We noticed this today when the trades showed up on public...
Notable ETF Inflow Detected - IXUS, PDD, NU, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where w...

Teva Releases Q3 2025 Aide Memoire
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial re...

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma...
November 7th Options Now Available For Teva Pharmaceutical Industries (TEVA)
Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News
TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News
Is Teva Pharmaceutical Indus Gaining or Losing Market Support?
Teva Pharmaceutical Indus's (NYSE: TEVA) short interest as a percent of float has risen 9.14% since its last report. According to exchange reported data, there are now 50.51 million shares sold short...
Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan
Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan

Bausch, Teva face lawsuit for delay in generic version of Xifaxan
Bausch Health and Teva face an antitrust lawsuit for allegedly delaying generic Xifaxan. Read more here.
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Teva Pharmaceutical Industries Limited - Special Call
Teva (TEVA) Highlights Schizophrenia Drug Portfolio at Annual Meeting
Teva (TEVA) Highlights Schizophrenia Drug Portfolio at Annual Meeting
Teva (TEVA) Reports Positive Feedback on AUSTEDO XR from Patient Survey
Teva (TEVA) Reports Positive Feedback on AUSTEDO XR from Patient Survey

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the pres...
HEFA, EFA, TEVA, MNDY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Currency Hedged MSCI EAFE ETF (Symbol: HEFA) where we have det...

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place fr...

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 202...
Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)
Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)